Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Celldex Therapeutics (CLDX) over the last 16 years, with Q2 2025 value amounting to 7784.79%.

  • Celldex Therapeutics' EBITDA Margin fell 63313900.0% to 7784.79% in Q2 2025 from the same period last year, while for Sep 2025 it was 8694.42%, marking a year-over-year decrease of 71815500.0%. This contributed to the annual value of 2248.68% for FY2024, which is 2236700.0% down from last year.
  • Latest data reveals that Celldex Therapeutics reported EBITDA Margin of 7784.79% as of Q2 2025, which was down 63313900.0% from 7703.88% recorded in Q1 2025.
  • Celldex Therapeutics' 5-year EBITDA Margin high stood at 384.14% for Q2 2021, and its period low was 22412.88% during Q2 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 5201.99% (2021), whereas its average is 7172.01%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -220287500bps in 2022, then skyrocketed by 140089400bps in 2025.
  • Quarter analysis of 5 years shows Celldex Therapeutics' EBITDA Margin stood at 6228.14% in 2021, then skyrocketed by 75bps to 1557.04% in 2022, then skyrocketed by 34bps to 1019.92% in 2023, then plummeted by -309bps to 4175.83% in 2024, then plummeted by -86bps to 7784.79% in 2025.
  • Its last three reported values are 7784.79% in Q2 2025, 7703.88% for Q1 2025, and 4175.83% during Q4 2024.